GlassScriptPhysician profile
Wael Hejjo Refai
NPI 1205926789
$2,171.91
in general payments reported to CMS, 2019-2025
23 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $45.28 · 2021: $79.08 · 2022: $527 · 2023: $315 · 2024: $782 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,365.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $509.36 | 2020-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $360.03 | 2021-2025 | Entyvio, Glassia |
| Phathom Pharmaceuticals, INC. | $208.65 | 2023-2025 | Voquezna |
| Glaxosmithkline, LLC. | $155.83 | 2021-2024 | Trelegy Ellipta |
| Abbvie INC. | $130.22 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $127.29 | 2024 | Airsupra |
| Amgen INC. | $117.93 | 2022 | |
| Shionogi INC | $97.28 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $56.74 | 2022 | |
| Allergan, INC. | $56.71 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.30 | 2023 | Jardiance, Cyltezo |
| Genzyme Corporation | $47.80 | 2024 | |
| Genentech, INC. | $40.00 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.04 | 2019 | |
| Pulmonx Corporation | $26.63 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $24.36 | 2024 | Arcalyst |
| Grifols USA, LLC | $23.76 | 2022 | |
| Ardelyx, INC. | $22.35 | 2024 | Ibsrela |
| United Therapeutics Corporation | $21.69 | 2024 | Tyvaso |
| Exact Sciences Corporation | $19.08 | 2023 | Cologuard Collection Kit |
| Mallinckrodt Hospital Products INC. | $17.73 | 2023 | Terlivaz |
| Covis Pharma Gmbh | $16.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $9.86 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wael Refai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.